Pharmacology of Anticancer Drugs in the Elderly Population

Clinical Pharmacokinetics

Volumn 42, Issue 14, 2003, Pages 1213-1242

  Wildiers, Hans ^a   Highley, Martin S ^a,b   De Bruijn, Ernst A ^a   Van Oosterom, Allan T ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GYRASE INHIBITOR; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TEMOZOLOMIDE; TENIPOSIDE; TETRAZINE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; AGING; ALOPECIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARCINOMA; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TOLERABILITY; FLUSHING; FOOD DRUG INTERACTION; HUMAN; IMMUNE DEFICIENCY; LEUKOPENIA; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SNEEZING; SOMNOLENCE; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; FRAIL ELDERLY; HUMANS; NEOPLASMS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS;

EID: 0344514147     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342140-00003     Document Type: Review

References (213)

1. Vestal RE. Aging and pharmacology. Cancer 1997; 80: 1302-10
2. Johnson SL, Mayersohn M. Conrad KA. Gastrointestinal absorption as a function of age; xylose absorption in healthy adults. Clin Pharmacol Ther 1985; 38: 331-5
3. Skirvin JA, Lichtman SM. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 2002; 19: 25-42
4. Rossman I. Clinical geriatrics. 2nd ed. Philadelphia (PA): Lippincott, 1979: 23-52, 132, 137, 224-9
5. Wallace SM, Verbeeck RK. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 1987; 12: 41-72
6. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med 1990; 6: 257-67
7. Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet 2000; 38: 271-90
8. Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 1986; 11: 223-35
9. Schrijvers D, Highley M, De Bruyn E, et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999; 10: 147-53
10. Teicher BA, Ara G, Herbst R, et al. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. In Vivo 1997; 11: 301-11
11. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963-8
12. Urien S, Bree F, Breillout F, et al. Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol 1993; 32: 231-4
13. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993; 20: 43-9
14. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet 1989; 17: 236-63
15. Turner N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol 1992; 32: 271-302
16. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307: 652-9
17. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984; 2: 1404-13
18. Anderson RJ, Gambertoglio JG, Schrier RW. Clinical use of drugs in renal failure. Springfield (IL): Charles C. Thomas Publishers, 1976
19. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995; 21: 33-64
20. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-611
21. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 2000; 36: 1741-54
22. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-7
23. Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000; 14: 17-23
24. Rousseau A, Marquet P, Debord J, et al. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000; 38: 315-53
25. van den Bongard HJ, Mathot RA, Beijnen JH, et al. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000; 39: 345-67
26. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295-305
27. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 27-34
28. Balducci L. The geriatric cancer patient. Equal benefit from equal treatment. Cancer Control 2001; 8: 1-25
29. Balducci L, Lyman GH. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 2001; 19: 1583-5
30. Balducci L, Extermann M, Carreca I. Management of breast cancer in the older woman. Cancer Control 2001; 8: 431-41
31. Repetto L, Carreca I, Maraninchi D. et al. Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting. Crit Rev Oncol Hematol 2003; 45: 123-8
32. Lyman GH, Kuderer NM, Balducci L. Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol 2002; 9: 207-14
33. Ozer H. Reply to letter of Balducci and Lyman [letter]. J Clin Oncol 2003; 19: 1584
34. Loadman PM, Bibby MC. Pharmacokinetic drug interactions with anticancer drugs. Clin Pharmacokinet 1994; 26: 486-500
35. Chen H, Cantor A, Meyer J. et al. Can older cancer patients tolerate chemotherapy? Cancer 2003; 97: 1107-14
36. De Jr VV, Hubbard SM, Longo DL. The chemotherapy of lymphomas: looking back, moving forward: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1987; 47: 5810-24
37. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-5
38. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-8
39. Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am 2000; 14: 63-77
40. Lichtman SM, Skirvin JA. Pharmacology of antineoplastic agents in older cancer patients. Oncology (Huntingt) 2000; 14: 1743-55
41. Extermann M. Assessment of the older cancer patient. Proc Am Soc Clin Oncol 1999; 18: 357
42. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991; 20: 194-208
43. Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998; 34: 33-46
44. Juma FD. Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol 1984; 26: 591-3
45. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000; 18: 521-9
46. Rudd GN, Hartley JA, Souhami RL. Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals. Cancer Chemother Pharmacol 1995; 35: 323-6
47. Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor, identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998; 16: 2352-8
48. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94: 33-8
49. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42
50. Lind MJ, Margison JM, Cerny T, et al. The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol 1990; 30: 140-3
51. Lind MJ, Margison JM, Cerny T, et al. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 1989; 25: 139-42
52. Meanwell CA, Blake AE, Kelly KA, et al. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986; 22: 815-9
53. De Pas T, Curigliano G, Catania C, et al. Ifosfamide in the elderly. Clinical considerations for a better drug management. Crit Rev Oncol Hematol 2000; 33: 129-35
54. Singer JM, Hartley JM, Brennan C, et al. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration. a randomized cross-over study. Br J Cancer 1998; 77: 978-84
55. Adair CG, Bridges JM, Desai ZR. Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? Cancer Chemother Pharmacol 1986; 17: 99-102
56. Hartvig P, Simonsson B, Oberg G, et al. Inter-and intraindividual differences in oral chlorambucil pharmacokinetics. Eur J Clin Pharmacol 1988; 35: 551-4
57. Levis A, Depaoli L, Bertini M, et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 1996; 81: 450-6
58. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441-7
59. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66
60. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999; 81: 1022-30
61. Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000; 17: 1284-9
62. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39: 155-65
63. Miller CB, Piantadosi S, Vogelsang GB, et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 1996; 14: 1327-32
64. Yamamoto N, Tamura T, Maeda M, et al. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 1995; 36: 102-6
65. Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin. relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5: 304-9
66. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997; 13: 169-83
67. Hrushesky WJ, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med 1984; 76: 579-84
68. Cubillo A, Cornide M, Lopez JL, et al. Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol 2001; 24: 192-7
69. Kubota K, Furuse K, Kawahara M, et al. Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40: 469-74
70. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-81
71. Chiara S, Lionetto R, Vincenti M, et al. Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. Crit Rev Oncol Hematol 2001; 37: 27-34
72. Martins SJ, Pereira JR, Ikari FK, et al. Chemotherapy with cisplatin and vinorelbin for elderly non-small-cell lung cancer patients [abstract no. 1804]. Proc Am Soc Clin Oncol 1999.
73. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12
74. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995; 13: 26-32
75. Genvresse I, Lange C, Schanz J, et al. Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. Anticancer Drugs 2001; 12: 345-9
76. van der Vijgh WJ. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991; 21: 242-61
77. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56
78. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-80
79. van Warmerdam LJ, Rodenhuis S, Bokkel Huinink WW, et al. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 1996; 37: 266-70
80. Egorin MJ. Further refinement of carboplatin dosing. J Natl Cancer Inst 1995; 87: 555-7
81. Fujiwara Y, Takahashi T, Yamakido M, et al. Re: prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1997; 89: 260-2
82. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 1998; 16: 255-60
83. Nannan P, van Warmerdam LJ, Huizing MT, et al. A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel. J Cancer Res Clin Oncol 1999; 125: 615-20
84. Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 2000; 45: 157-64
85. Levi F, Metzger G, Massari C, et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38: 1-21
86. Devita VT, Hellman S, Osenberg SA. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers, 1997
87. Gauvin A, Pinguet F, Culine S, et al. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. Cancer Chemother Pharmacol 2002; 49: 48-56
88. Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996; 59: 32-40
89. Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997; 33: 301-3
90. Gauvin A, Pinguet F, Culine S, et al. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 2000; 6: 2690-5
91. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72
92. Marty M, Fumoleau P, Adenis A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001; 12: 1643-9
93. Puozzo C, Gridelli C, Jaworski M. Pharmacokinetics of Navelbine oral in elderly patients. Tumori 2002; 88: S75-6
94. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998; 16: 1811-9
95. Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994; 27: 256-69
96. Akerley W, Sikov WM, Cummings F, et al. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol 1997; 24: S17-87
97. Fidias P, Supko JG, Martins R, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001; 7: 3942-9
98. Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 2002; 11: 103-18
99. Taylor CW, Wang LM, List AF, et al. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer 1997; 33: 1693-8
100. Nakamura Y, Sekine I, Furuse K, et al. Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. Cancer Chemother Pharmacol 2000; 46: 114-8
101. Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255-8
102. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99-114
103. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-96
104. Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001; 19: 163-9
105. Hainsworth JD, Burris III HA, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16: 2164-8
106. Hainsworth JD, Vokes EE. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 2001; 28: 22-7
107. Hainsworth JD, Burris III HA, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma: a Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000; 89: 328-33
108. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994; 12: 1458-67
109. Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223-52
110. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374-7
111. Hande K, Messenger M, Wagner J, et al. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin Cancer Res 1999; 5: 2742-7
112. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial: Medical Research Council Lung Cancer Working Party. Lancet 1996; 348: 563-6
113. el Yazigi A, Ezzat A, Berry J, et al. Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient. J Clin Pharmacol 2000; 40: 153-60
114. Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 1994; 34 Suppl.: S69-75
115. Miller AA, Rosner GL, Ratain MJ, et al. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res 1997; 3: 719-25
116. Mick R, Ratain MJ. Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 1991; 83: 1560-4
117. Stewart CF, Arbuck SG, Fleming RA, et al. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 1991; 50: 385-93
118. Stewart CF, Arbuck SG, Fleming RA, et al. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990; 8: 1874-9
119. Stewart CF, Fleming RA, Arbuck SG, et al. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 1990; 50: 6854-6
120. Favaretto A, Ardizzoni A, Tixi L, et al. Full dose chemotherapy plus lenograstim and low dose CT in elderly SCLC patients: a Phase II randomised FONICAP-GSTPV study [abstract]. Lung Cancer 2000; 29 Suppl. 1: 9
121. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997; 33: 245-59
122. van Groeningen CJ, van der Vijgh WJ, Baars JJ, et al. Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines. Clin Cancer Res 2000; 6: 1342-6
123. Pazdur R, Zinner R, Rothernberg ML, et al. Age as a risk factor in irinotecan treatment of 5-FU-refractory colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 921
124. Schaaf L, Ichhpurani N, Elfring G, et al. Influence of age on the pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G, in patients with previously treated colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 708
125. Lichtman SM. Recent developments in the pharmacology of anticancer drugs in the elderly. Curr Opin Oncol 1998; 10: 572-9
126. Miya T, Goya T, Fujii H, et al. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 2001; 19: 61-7
127. Herben VM, Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996; 31: 85-102
128. O'Reilly S, Armstrong DK, Grochow LB. Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. Gynecol Oncol 1997; 67: 329-30
129. Montazeri A, Boucaud M, Lokiec F, et al. Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol 2000; 46: 375-81
130. van Warmerdam LJ, Verweij J, Rosing H, et al. Limited sampling models for topotecan pharmacokinetics. Ann Oncol 1994; 5: 259-64
131. Boucaud M, Pinguet F, Poujol S, et al. Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. Eur J Cancer 2001; 37: 2357-64
132. Bressolle F, Bologna C, Kinowski JM, et al. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis: a comparison with young patients. J Rheumatol 1997; 24: 1903-9
133. Kristensen LO, Weismann K, Hutters L. Renal function and the rate of disappearance of methotrexate from serum. Eur J Clin Pharmacol 1975; 8: 439-44
134. Borkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Phamacol 1994; 33: 493-6
135. Ng S, Rosenthal MA, Ashley D, et al. High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro-oncol 2000; 2: 40-4
136. Chu E, Allegra CJ. Cancer chemotherapy and biotherapy: principles and practice. In: Chabner BA, Longo DL, editors. Antifolates. 2nd ed. Philadelphia: Lippincott-Raven. 1996: 109-48
137. Thyss A, Milano G, Kubar J, et al. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986; 1: 256-8
138. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-37
139. Port RE, Daniel B, Ding RW, et al. Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. Oncology 1991; 48: 277-81
140. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992; 10: 1171-5
141. Young AM, Daryanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil? Clin Pharmacokinet 1999; 36: 391-8
142. Keizer HJ, de Bruijn EA, Tjaden UR, et al. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)- 2′-deoxyuridine. J Cancer Res Clin Oncol 1994; 120: 545-9
143. de Bruijn EA, Driessen O, Leeflang P, et al. Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model. Cancer Treat Rep 1987; 71: 1267-9
144. Harvey VJ, Slevin ML, Dilloway MR, et al. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol 1984; 18: 421-30
145. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer 1995; 75: 11-7
146. Weinerman B, Rayner H, Venne A, et al. Increased incidence and severity of stomatitis in women treated with 5-fluorouracil and leucovorin [abstract]. Proc Am Soc Clin Oncol 1998; 17: 1176
147. Petrelli N, Douglass Jr HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial: Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419-26
148. Sargent D, Goldberg R, MacDonald J, et al. Adjuvant chemotherapy for colon cancer is beneficial without significantly increased toxicity in elderly patients: results from a 3351-pt meta-analysis [abstract no. 933]. Proc Am Soc Clin Oncol 2000; 19.
149. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer, the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000; 18: 1412-22
150. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-106
151. Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86: 1367-72
152. Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998; 4: 941-8
153. Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol 1999; 43: 309-15
154. Reigner B, Blesch K. Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40: 85-104
155. Cassidy J, Twelves C, Cameron D, et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999; 44: 453-60
156. Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49: 225-34
157. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5: 1696-702
158. Johnson SA. Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. Clin Pharmacokinet 2000; 39: 5-26
159. Iwakiri R, Ohta M, Mikoshiba M, et al. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases. Int J Hematol 2002; 75: 45-50
160. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol 1990; 8: 272-9
161. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001; 39: 275-87
162. Esumi Y, Mitsugi K, Seki H, et al. Placental transfer, lacteal transfer and plasma protein binding of gemcitabine. Xenobiotica 1994; 24: 957-64
163. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction. Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18: 2780-7
164. Shepherd FA, Abratt RP, Anderson H, et al. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 1997; 24: S7-50-S7-55
165. Martin C, Ardizzoni A, Rosso R. Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging (Milano) 1997; 9: 297-303
166. Martoni A, Di Fabio F, Guaraldi M, et al. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer. Am J Clin Oncol 2001; 24: 614-7
167. Adkins JC, Peters DH, Markham A. Fludarabine: an update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005-37
168. Martell RE, Peterson BL, Cohen HJ, et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 2002; 50: 37-45
169. Marotta G, Bigazzi C, Lenoci M, et al. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85: 1268-70
170. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 1998; 34: 347-58
171. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988; 15: 15-31
172. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 1983; 43: 4467-9
173. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-7
174. Benjamin RS. Pharmacokinetics of adriamycin (NSC-123127) in patients with sarcomas. Cancer Chemother Rep 1974; 58: 271-3
175. Cova D, Beretta G, Balducci L. Cancer chemotherapy in the older person: comprehensive geriatric oncology. Amsterdam, The Netherlands: Harwood Academic Publishers, 1998: 429-42
176. Jacobson JO, Grossbard M, Shulman LN. CHOP chemotherapy with G-CSF in elderly patients with intermediate grade lymphoma: full dose intensity is possible. Proc Am Soc Clin Oncol 1988; 7: 17
177. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92
178. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-9
179. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-32
180. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25-36
181. Ibrahim NK, Buzdar AU, Asmar L, et al. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the MD Anderson experience, with long-term follow-up. Ann Oncol 2000; 11: 1597-601
182. Sulkes A, Stemmer SM. Doxorubicin-based chemotherapy in the elderly. Ann Oncol 2001; 12: 1180-1
183. Ibrahim NK, Frye DK, Buzdar AU, et al. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome. Arch Intern Med 1996; 156: 882-8
184. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352: 930-42
185. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000; 18: 1709-17
186. Sonneveld P, de Ridder M, van der LH, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530-9
187. Wylie JP, Cowan RA, Radford JA, et al. A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma. Clin Oncol (R Coll Radiol) 2000; 12: 153-7
188. Meyer RM, Browman GP, Samosh ML, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2386-93
189. Weekes CD, Vose JM, Lynch JC, et al. Hodgkin's disease in the elderly, improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 2002; 20: 1087-93
190. Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1996; 22: 483-93
191. Guerci A, Lederlin P, Reyes F, et al. Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen: Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 1996; 7: 966-9
192. Bernardi D. Is it possible to use anthracyclines in patients older than 70 years? Pro. Tumori 2002; 88: S133-5
193. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974-9
194. Zinzani PL, Gherlinzoni F, Storti S, et al. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 2002; 13: 1364-9
195. Buzdar AU, Marcus C, Smith TL, et al. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985; 55: 2761-5
196. Kokenberg E, Sonneveld P, Sizoo W, et al. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. J Clin Oncol 1988; 6: 802-12
197. Platel D, Pouna P, Bonoron-Adele S, et al. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anticancer Drugs 1999; 10: 671-6
198. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 1993; 24: 275-88
199. Buckley MM, Lamb HM. Oral idarubicin: a review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer. Drugs Aging 1997; 11: 61-86
200. Leoni F, Ciolli S, Giuliani G, et al. Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. Br J Haematol 1995; 90: 169-74
201. Robert J. Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 1994; 26: 428-38
202. Anon. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol 1988; 6: 976-82
203. Nicolella D, Grimaldi G, Colantuoni G, et al. Weekly low dose epirubicin in elderly cancer patients. Tumori 1996; 82: 369-71
204. Twelves CJ, Dobbs NA, Michael Y, et al. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 1992; 66: 765-9
205. Wiseman LR, Spencer CM. Mitoxantrone: a review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997; 10: 473-85
206. Ehninger G, Schuler U, Proksch B, et al. Pharmacokinetics and metabolism of mitoxantrone: a review. Clin Pharmacokinet 1990; 18: 365-80
207. Mainwaring PN, Cunningham D, Gregory W, et al. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood 2001; 97: 2991-7
208. Repetto L, Vannozzi MO, Balleari E, et al. Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells. Anticancer Res 1999; 19: 879-84
209. Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol 1992; 19: 3-8
210. Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982; 9: 34-51
211. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120: 617-24
212. Verweij J, den Hartigh J, Stuurman M, et al. Relationship between clinical parameters and pharmacokinetics of mitomycin C. J Cancer Res Clin Oncol 1987; 113: 91-4
213. Miya T, Sasaki Y, Karato A, et al. Pharmacokinetic study of mitomycin C with emphasis on the influence of aging. Jpn J Cancer Res 1992; 83: 1382-5